Bank of America Securities analyst Tim Anderson has reiterated their bullish stance on GILD stock, giving a Buy rating today.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tim Anderson’s rating is based on Gilead Sciences’ strong financial performance and promising future prospects. The company’s Q4 results exceeded expectations for both revenue and earnings per share, partly due to strategic inventory management. Additionally, the guidance for 2025 remains optimistic, with projected revenues and earnings per share suggesting continued growth.
In particular, the successful performance of Biktarvy, a key product with high operating margins, reinforces confidence in Gilead’s long-term potential. Furthermore, the upcoming launch of lenacapavir for HIV prevention is anticipated to be a significant growth driver. The valuation remains attractive compared to its peers, justifying a higher price objective, and the company benefits from a stable long-term outlook with minimal patent expiration risks until the early 2030s.
In another report released today, DZ BANK AG also upgraded the stock to a Buy with a $108.00 price target.